Percutaneous Coronary Intervention for Tortuous Left Anterior Descending Artery with Bioresorbable Vascular Scaffold via the Transradial Approach.
作者信息
Lee Wei-Chieh, Fang Hsiu-Yu, Wu Chiung-Jen
机构信息
Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
出版信息
Acta Cardiol Sin. 2018 Nov;34(6):530-532. doi: 10.6515/ACS.201811_34(6).20180818B.
Abstract
摘要
相似文献
1
Percutaneous Coronary Intervention for Tortuous Left Anterior Descending Artery with Bioresorbable Vascular Scaffold via the Transradial Approach.
Acta Cardiol Sin. 2018 Nov;34(6):530-532. doi: 10.6515/ACS.201811_34(6).20180818B.
2
Bioresorbable Vascular Scaffold Stent Delivered to Tortuous Lesions by Using the "Five-in-Six" System.
Acta Cardiol Sin. 2017 Nov;33(6):672-675. doi: 10.6515/ACS20170413A.
3
The utility of extension catheters in transradial percutaneous coronary intervention.
J Invasive Cardiol. 2015 Jan;27(1):28-32.
4
Very late bioresorbable scaffold thrombosis and reoccurrence of dissection two years later chronic total occlusion recanalization of the left anterior descending artery.
World J Cardiol. 2017 Aug 26;9(8):710-714. doi: 10.4330/wjc.v9.i8.710.
5
Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial.
JACC Cardiovasc Interv. 2017 Apr 24;10(8):774-782. doi: 10.1016/j.jcin.2017.01.022.
6
Incidence and significance of side branch occlusions following bioresorbable scaffold implantation for long left anterior descending artery lesions.
Int J Cardiol. 2016 Nov 1;222:674-675. doi: 10.1016/j.ijcard.2016.08.060. Epub 2016 Aug 4.
7
The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment.
Kardiol Pol. 2016;74(7):627-33. doi: 10.5603/KP.a2015.0250. Epub 2016 Jan 18.
8
Platelet counts on admission affect coronary flow, myocardial perfusion and left ventricular systolic function after primary percutaneous coronary intervention.
Eur Heart J Acute Cardiovasc Care. 2017 Oct;6(7):632-639. doi: 10.1177/2048872616643690. Epub 2016 Apr 11.
9
Retrograde percutaneous recanalization of chronic total occlusion of the left anterior descending artery through an extremely tortuous right ventricular branch.
Cardiovasc Interv Ther. 2012 Sep;27(3):210-3. doi: 10.1007/s12928-012-0110-7. Epub 2012 Jun 19.
10
Immediate results of percutaneous coronary intervention for unprotected left main coronary artery stenoses: transradial versus transfemoral approach.
Chang Gung Med J. 2008 Mar-Apr;31(2):190-200.
引用本文的文献
1
Efficacy and Biosafety of a New Bioresorbable Vascular Scaffold Covered with Biodegradable Film in Rabbits: An In Vivo Study.
Acta Cardiol Sin. 2020 Nov;36(6):660-666. doi: 10.6515/ACS.202011_36(6).20200421B.
2
Use of Intracoronary Imaging for Optimization of Bioresorbable Vascular Scaffold Implantation and Left Main Disease.
Acta Cardiol Sin. 2019 Jul;35(4):437-438. doi: 10.6515/ACS.201907_35(4).20190306A.
本文引用的文献
1
Thirty-Day and One-Year Clinical Outcomes of Bioresorbable Vascular Scaffold Implantation: A Single-Center Experience.
Acta Cardiol Sin. 2017 Nov;33(6):614-623. doi: 10.6515/ACS20170714A.
2
Everolimus-Eluting Bioresorbable Vascular Scaffold in Real World Practice - A Single Center Experience.
Acta Cardiol Sin. 2017 May;33(3):250-257. doi: 10.6515/acs20160901a.
3
Bioresorbable scaffold - A magic bullet for the treatment of coronary artery disease?
Int J Cardiol. 2016 Jul 15;215:47-59. doi: 10.1016/j.ijcard.2016.04.027. Epub 2016 Apr 12.
4
Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users : A position statement on the use of bioresorbable vascular scaffolds in the Netherlands.
Neth Heart J. 2015 Mar;23(3):161-5. doi: 10.1007/s12471-015-0651-3.
5
Going around the bend: deep inspiration facilitates difficult stent delivery in the native coronary arteries.
Tex Heart Inst J. 2011;38(3):270-4.
6
Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
Circulation. 2010 Nov 30;122(22):2301-12. doi: 10.1161/CIRCULATIONAHA.110.970772. Epub 2010 Nov 15.
Zotero 插件